IDKmonitor® Infliximab Total ADA ELISA


Available on backorder

Product Specifications

Method: ELISA
Sample Type (Matrix): Serum, EDTA Plasma
Sample Volume: 25 µl
Species: Human
Incubation time: 3h
Size: 96 wells
Regulatory Status: For research use only in the U.S.


The IDKmonitor® Infliximab Total ADA ELISA is intended for the determination of human antibodies against TNF-alpha blocker infliximab (e.g. REMICADE®) in the presence of infliximab in EDTA plasma and serum.

For research use only. Not for use in diagnostic procedures.

For Laboratory Professional Use Only.

This is the RUO version of Immundiagnostik part number K 9654.

Test Principle of the IDKmonitor® Infliximab Total ADA ELISA

This ELISA is used for the determination of antibodies against TNFα-Blocker infliximab (e. g. REMICADE®).

During sample preparation, the anti-drug antibodies (ADA) are separated from the therapeutic antibody in order to acquire free ADA. By adding the conjugate (peroxidase-labeled therapeutic antibody) and the tracer (biotinylated therapeutic antibody), the unmarked therapeutic antibodies are replaced and the marked antibodies can form a complex with the ADA. This complex binds via biotin to the streptavidin-coated microtiter plate. It is detected via the peroxidase conjugate with the peroxidase converting the substrate TMB to a blue product.

The enzymatic reaction is stopped by adding an acidic solution. The samples convert from blue to yellow. The color change should be measured in a photometer at 450 nm. The interpretation is made using the cut-off control.

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors